Antipsychotic prescription filling in patients with schizophrenia or schizoaffective disorder

Journal of Clinical Psychopharmacology

Volumn 33, Issue 6, 2013, Pages 759-765

  Reutfors, Johan ^a   Brandt, Lena ^a   Stephansson, Olof ^a   Kieler, Helle ^a   Andersen, Morten ^a   Bodén, Robert ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

adherence,hospitalization; antipsychotics; cohort study; schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL ACETATE;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; EDUCATIONAL STATUS; FEMALE; HAZARD RATIO; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PSYCHOTHERAPY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUBSTANCE ABUSE;

ADULT; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MEDICATION ADHERENCE; PROPORTIONAL HAZARDS MODELS; PSYCHOTIC DISORDERS; REGISTRIES; REGRESSION ANALYSIS; SCHIZOPHRENIA; SWEDEN; TIME FACTORS; YOUNG ADULT;

EID: 84888133304     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182a1cd2e     Document Type: Article

References (42)

1. Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25(5):567-620.
2. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71-93.
3. Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry. 2006;67(suppl 5):3-8.
4. Novick D, Haro JM, Suarez D, et al. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010;176(2-3):109-113.
5. Bodén R, Brandt L, Kieler H, et al. Early non-adherence to medication and other risk factors for rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Res. 2011;133(1-3):36-41.
6. Hawton K, Sutton L, Haw C, et al. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry. 2005;187:9-20.
7. Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf. 2003;12(5):423-424.
8. Ascher-Svanum H, Faries DE, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67(3):453-460.
9. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161(4):692-699.
10. Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull. 2008;34(1):173-180.
11. Thieda P, Beard S, Richter A, et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatric Serv. 2003;54(4):508-516.
12. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
13. Day JC, Bentall RP, Roberts C, et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry. 2005;62(7):717-724.
14. Kikkert MJ, Barbui C, Koeter MW, et al. Assessment of medication adherence in patients with schizophrenia: the Achilles heel of adherence research. J Nerv Ment Dis. 2008;196(4):274-281.
15. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892-909.
16. Olfson M, Mechanic D, Hansell S, et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatric Serv. 2000;51(2):216-222.
17. Velligan DI, Lam YW, Glahn DC, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull. 2006;32(4):724-742.
18. Byerly M, Fisher R, Whatley K, et al. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res. 2005;133(2-3):129-133.
19. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatric Serv. 1998;49(2):196-201.
20. Clayton CD, Veach J, Macfadden W, et al. Assessment of clinician awareness of non-adherence using a new structured rating scale. J Psychiatr Pract. 2010;16(3):164-169.
21. Velligan DI, Wang M, Diamond P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatric Serv. 2007;58(9):1187-1192.
22. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1997;23(4):637-651.
23. Owen RR, Fischer EP, Booth BM, et al. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatric Serv. 1996;47(8):853-858.
24. Perkins DO, Gu H, Weiden PJ, et al. Predictors of treatment discontinuation and medication non-adherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008;69(1):106-113.
25. Cuffel BJ, Alford J, Fischer EP, et al. Awareness of illness in schizophrenia and outpatient treatment adherence. J Nerv Ment Dis. 1996;184(11):653-659.
26. Jonsdottir H, Opjordsmoen S, Birkenaes AB, et al. Predictors of medication adherence in patients with schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2013;127(1):23-33.
27. Rijcken CA, Tobi H, Vergouwen AC, et al. Refill rate of antipsychotic drugs: an easy and inexpensive method to monitor patients' compliance by using computerised pharmacy data. Pharmacoepidemiol Drug Saf. 2004;13(6):365-370.
28. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105-116.
29. Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.
30. Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug RegisterVopportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726-735.
31. World Health Organization. WHO Collaboration Centre for Drugs Statistics Methodology. Available at: http://www.whocc.no/atcddd/. Accessed January 26, 2013.
32. Baethge C. Long-term treatment of schizoaffective disorder: review and recommendations. Pharmacopsychiatry. 2003;36(2):45-56.
33. Storm A, Andersen SE, Benfeldt E, et al. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol. 2008;59(1):27-33.
34. Hudson TJ, Owen RR, Thrush CR, et al. A pilot study of barriers to medication adherence in schizophrenia. J Clin Psychiatry. 2004;65(2):211-216.
35. Tiihonen J, Haukka J, Taylor M, et al. A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia. Am J Psychiatry. 2011;168(6):603-609.
36. Swedish Psychiatric Association. SchizophreniaVclinical guidelines [in Swedish]. 2009. Available at: http://www.svenskpsykiatri.se/Riktlinjer/rp- schizofreni-tryck.pdf. Accessed January 26, 2013.
37. West JC, Marcus SC, Wilk J, et al. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull. 2008;34(5):995-1001.
38. Desai RA, Dausey DJ, Rosenheck RA. Mental health service delivery and suicide risk: the role of individual patient and facility factors. Am J Psychiatry. 2005;162(2):311-318.
39. Qin P, Nordentoft M. Suicide risk in relation to psychiatric hospitalization: evidence based on longitudinal registers. Arch Gen Psychiatry. 2005;62(4):427-432.
40. Appleby L, Desai PN, Luchins DJ, et al. Length of stay and recidivism in schizophrenia: a study of public psychiatric hospital patients. Am J Psychiatry. 1993;150(1):72-76.
41. Lin HC, Tian WH, Chen CS, et al. The association between readmission rates and length of stay for schizophrenia: a 3-year population-based study. Schizophr Res. 2006;83(2-3):211-214.
42. Cooper D, Moisan J, Gregoire JP. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry. 2007;68(6):818-825.